Arch Biopartners Inc. (TSXV: ARCH)
Canada
· Delayed Price · Currency is CAD 1.940
+0.010 (0.52%)
Jan 2, 2025, 3:59 PM EST
Arch Biopartners Revenue
Arch Biopartners had revenue of 1.38M CAD in the twelve months ending June 30, 2024, down -44.41% year-over-year. In the fiscal year ending September 30, 2023, Arch Biopartners had annual revenue of 1.98M with 105.63% growth.
Revenue (ttm)
1.38M
Revenue Growth
-44.41%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
125.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | 67.89K | -25.99K | -27.69% |
| Sep 30, 2019 | 93.88K | - | - |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
| Sep 30, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries | 1.51B |
| WELL Health Technologies | 957.69M |
| Curaleaf Holdings | 1.83B |
| dentalcorp Holdings | 1.51B |
| Trulieve Cannabis | 1.58B |
| Sienna Senior Living | 867.55M |
| Cronos Group | 150.26M |
| Extendicare | 1.42B |
Arch Biopartners News
- 7 weeks ago - Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - GlobeNewsWire
- 2 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 3 months ago - Closes Units for Debt Settlement - GlobeNewsWire
- 3 months ago - Units for Debt Settlement - GlobeNewsWire
- 4 months ago - Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) - GlobeNewsWire
- 5 months ago - Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins - GlobeNewsWire
- 5 months ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 5 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire